Antibody Profiling Panel for Prostate Cancer Detection
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current prostate cancer detection methods, such as PSA screening, face challenges with low sensitivity and specificity, particularly in the intermediate PSA range, leading to unnecessary biopsies and inconclusive results.
Innovation Solution
Development of an antibody profiling panel comprising polypeptide probes specific to proteins encoded by certain genes, which can be used to detect autoantibodies indicative of prostate, lung, breast, or colon cancer, allowing for more precise characterization and staging of cancer.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Reliability
If PSA screening is used for prostate cancer detection, then early detection capability is improved, but sensitivity and specificity deteriorate due to false positives from non-malignant conditions
Solution Approach 1:
The invention segments the single PSA measurement into multiple distinct antibody targets (including but not limited to PSA, p30, p24, and other prostate-associated antigens). Each antibody in the panel detects a specific antigen, allowing the system to differentiate between benign and malignant conditions through patterns of antibody responses rather than relying on a single imprecise measurement.
Solution Approach 2:
The antibody profiling panel serves multiple functions simultaneously: it detects prostate cancer, differentiates between benign and malignant conditions, provides prognostic information about cancer aggressiveness, and reduces unnecessary biopsies. This multi-functional approach replaces the limited single-function PSA test, improving both reliability and measurement precision across multiple diagnostic dimensions.
2Reliability
If PSA screening threshold is set to detect intermediate range cancers, then more cancers are detected, but false positives increase leading to unnecessary biopsies
Solution Approach 1:
The antibody profiling panel performs preliminary diagnostic action before biopsy is considered. By measuring the pattern of autoantibodies against multiple prostate-associated antigens, the system can preliminarily distinguish between benign conditions requiring biopsy and malignant conditions where biopsy is warranted, thereby reducing unnecessary biopsy procedures while maintaining high cancer detection rates.
Solution Approach 2:
The panel of autoantibodies serves as an intermediary diagnostic tool between the initial PSA screening and the invasive biopsy procedure. This intermediary test provides additional discriminatory information that mediates the decision-making process, allowing clinicians to avoid unnecessary biopsies while ensuring that true cancer cases are identified for further investigation.
3Ease of operation
If PSA level is used as sole marker, then screening simplicity is maintained, but information about cancer aggressiveness is lost
Solution Approach 1:
The invention segments the diagnostic information into multiple distinct antibody responses, each providing specific prognostic information about cancer characteristics. Rather than a single PSA value that loses information, the panel measures multiple autoantibodies (such as anti-PSA, anti-p30, anti-p24, and others) whose presence, absence, or relative levels provide segmented information about tumor aggressiveness, stage, and prognosis, all while maintaining a relatively simple blood test format.
Applied Scientific Principles
This section explains which scientific principles are used to turn an abstract innovation direction into a practical engineering solution.
Function Achieved in This Case
The antibody profiling panel provides high sensitivity and specificity in detecting cancer, reducing the need for unnecessary biopsies and improving the accuracy of cancer characterization and staging.
Implementation Method 1
contacting a biological sample obtained from the subject with one or more polypeptide probes... wherein each of the probes in the plurality of polypeptide probes is capable of being specifically bound by an antibody
Data Source
AI summary
The present disclosure provides compositions and methods for using one or more polypeptide probes to profile an immune response. The polypeptide probe can be used to detect one or more antibodies from a sample. Furthermore, the present disclosure provides methods and compositions for characterizing a cancer based on the detection of one or more antibodies, such as autoantibodies.